Document Detail

Perfluorocarbon-based oxygen delivery.
MedLine Citation:
PMID:  17090429     Owner:  NLM     Status:  MEDLINE    
The basic properties of perfluorocarbons (PFCs) and PFC emulsions relevant to their use as oxygen delivery systems are briefly reviewed. The key issues related to the selection of an appropriate, readily excretable PFC and the engineering of a stable injectable PFC emulsion are discussed. Oxygent, a terminally heat-sterilized, injectable 60% w/v PFC emulsion made primarily of F-octyl bromide and a few percent of F-decyl bromide, with egg phospholipids as an emulsifier, has been developed. Its efficacy in avoiding and reducing red cell transfusion during surgery has been established during a Phase III clinical evaluation. Another Phase III clinical trial in cardiopulmonary bypass surgery, with a protocol that included both augmented-acute normovolemic hemodilution and intraoperative autologous donation, has, however, been interrupted following the observation of adverse events. Data analysis assigned these events to an inappropriate study protocol. A search for possible interactions between Oxygent and fluids present during cardiopulmonary bypass surgery detected no effect of the emulsion on hemostasis, hemolysis and blood rheology.
Jean G Riess
Related Documents :
11591399 - Sex ratio and birth weights of infants born as a result of blastocyst transfers compare...
9341619 - Birth of a healthy female after intracytoplasmic sperm injection of cryopreserved human...
24265599 - Whole blood gene expression profiles to assess pathogenesis and disease severity in inf...
21369809 - Reduced intubation rates for infants after introduction of high-flow nasal prong oxygen...
8006149 - Birth characteristics and perinatal outcome of babies conceived from cryopreserved embr...
24794369 - Safety and immunogenicity of tetanus diphtheria and acellular pertussis (tdap) immuniza...
9730199 - Legionella pneumonia in neonates: a literature review.
7546639 - Onset of speech-like vocalizations in infants with down syndrome.
14742109 - Birth outcomes across ethnic groups of women in nepal.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Artificial cells, blood substitutes, and immobilization biotechnology     Volume:  34     ISSN:  1073-1199     ISO Abbreviation:  Artif Cells Blood Substit Immobil Biotechnol     Publication Date:  2006  
Date Detail:
Created Date:  2006-11-08     Completed Date:  2006-12-21     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9431307     Medline TA:  Artif Cells Blood Substit Immobil Biotechnol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  567-80     Citation Subset:  IM    
MRI Institute, University of California at San Diego and Alliance Pharmaceutical Corp., San Diego, CA 92103, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Substitutes / chemistry,  pharmacology,  therapeutic use*
Clinical Trials as Topic
Fluorocarbons / chemistry,  therapeutic use*
Hemolysis / drug effects*
Hemorheology / drug effects*
Hemostasis / drug effects*
Reg. No./Substance:
0/Blood Substitutes; 0/Emulsions; 0/Fluorocarbons; 423-55-2/perflubron

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evolution of artificial cells using nanobiotechnology of hemoglobin based RBC blood substitute as an...
Next Document:  Hemoglobin-vesicles as a transfusion alternative.